Department of Dermatology, Peking University First Hospital, Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, National Clinical Research Center for Skin and Immune Disease, Beijing, China; Center for the Study of Itch and Sensory Disorders, Washington University School of Medicine, St. Louis, USA.
Center for the Study of Itch and Sensory Disorders, Washington University School of Medicine, St. Louis, USA; Department of Anesthesiology, Washington University School of Medicine, St. Louis, USA; Current Address: Department of Pediatrics, Washington University School of Medicine, St. Louis, USA.
J Invest Dermatol. 2020 Aug;140(8):1524-1532. doi: 10.1016/j.jid.2020.01.012. Epub 2020 Jan 29.
Animal studies have suggested that transient receptor potential ion channels and G-protein coupled receptors play important roles in itch transmission. TRPV3 gain-of-function mutations have been identified in patients with Olmsted syndrome, which is associated with severe pruritus. However, the mechanisms causing itch remain poorly understood. Here, we show that keratinocytes lacking TRPV3 impair the function of protease-activated receptor 2 (PAR2), resulting in reduced neuronal activation and scratching behavior in response to PAR2 agonists. Moreover, we show that TRPV3 and PAR2 were upregulated in skin biopsies from patients and mice with atopic dermatitis, whereas their inhibition attenuated scratching and inflammatory responses in mouse atopic dermatitis models. These results reveal a previously unrecognized link between TRPV3 and PAR2 in keratinocytes to convey itch information and suggest that a blockade of PAR2 or TRPV3 individually or both may serve as a potential approach for antipruritic therapy in atopic dermatitis.
动物研究表明,瞬时受体电位离子通道和 G 蛋白偶联受体在瘙痒传递中发挥重要作用。在 Olmsted 综合征患者中发现 TRPV3 功能获得性突变,该综合征与严重瘙痒有关。然而,导致瘙痒的机制仍知之甚少。在这里,我们表明缺乏 TRPV3 的角质形成细胞会损害蛋白酶激活受体 2 (PAR2) 的功能,导致对 PAR2 激动剂的神经元激活和搔抓行为减少。此外,我们表明 TRPV3 和 PAR2 在特应性皮炎患者和小鼠的皮肤活检中上调,而其抑制作用可减轻小鼠特应性皮炎模型中的搔抓和炎症反应。这些结果揭示了角质形成细胞中 TRPV3 和 PAR2 之间以前未被认识的联系,以传递瘙痒信息,并表明单独阻断 PAR2 或 TRPV3 或两者都可能成为特应性皮炎止痒治疗的潜在方法。